INTRODUCTION
A factor inhibiting the migration of tumor cells has been obtained from different human lymphoid cell lines and murine lymphocytes stimulated with concanavalin A (1, 2) . In these investigations, target cells from various experimental tumors, including Ehrlich ascites and solid tumor, were used. We have reported that the migration of transplanted sarcoma cells and Ehrlich ascites tumor cells out of capillary tubes may be inhibited by the factor found in the culture superna-tants, when the spleen cells of BALB/c mice transplanted with sarcoma cells or immunized with killed sarcoma cells were stimulated in vitro with a 3 M KC1 extract of the sarcoma (3). In our previous study, it was shown that the regional lymph node lymphocytes from patients with cancer of the stomach , after a stimulation with gastric cancer extracts, produced a factor which inhibited the migration of gastric cancer cells and Ehrlich cells (4, 5) . In these lymph nodes , without cancer metastases or with small metastatic foci, immunoreactive changes were found. No essential difference in migration inhibition was observed with the following target cells: gastric cancer cells, transplanted sarcoma cells (in experiments) and Ehrlich cells.
The aim of this study was to determine whether the peripheral blood E rosette-forming cells (ERFC), CD4 + and CD8 + T cells would produce a factor inhibiting in vitro tumor-cell migration (TCM) by stimulation with cancer extracts .
The results of the study together with the data mentioned above could contribute to the interpretation of the factor, whose biological activity is expressed in inhibition of TCM, to be an in vivo protective phenomenon in tumor pathology.
MATERIALS AND METHODS
Patients: Peripheral blood mononuclear cells (PBMC) were obtained from 44 patients with gastric cancer (23 males and 21 females) , 66 women with breast cancer and controls. The patients whose cancer referred to the stages I and II in TNM system had undergone radical subtotal gastric resection , respectively total mastectomy and axillary dissection at the University Hospital of the Medical University, Pleven.
Patients with chronic ulcer of the stomach and fibrocystic disease of the breast as well as healthy persons were taken as controls. The microcultures of ERFC, CD4 + and CD8 + T cells were incubated at 37 C in a humid atmosphere of 5% CO2. Twelve days later, cancer extract of 20 pl was added to wells with growing microcultures for 24 hr. The culture supernatants were decanted and assayed for migration inhibition.
Then, the seeded cells in each well were removed with an automatic pipette and counted in a hemocytometer. This procedure defined the proliferation of the cells in microcultures at various initial cell concentrations (high and small). As a control, feeder cells were stimulated with PHA and an IL-2-containing supernatant.
Control microcultures of ERFC and CD4+ T cells from patients with gastric cancer were stimulated with extract of breast cancer. On the contrary, ERFC and CD4 + T cells from patients with breast cancer were stimulated with extract of gastric cancer, or were not stimulated with a cancer extract. 
Inhibition Effects of the Fractions of Crude Supernatants
Active crude supernatants were chromatographed on a Sephadex G-100 column, and six fractions with low protein contents (0.06-0.11 mg/ml) were isolated (Fig. 2) . IE against migration of Ehrlich cells was found with the fractions 4, 5 and 6; the factor was distributed in the range of molecular weights between 14,300 and 5,800 for the fraction 4 and lower than 5,800 for the fractions 5 and 6.
The fraction 6 did not appear in all cases.
DISCUSSION
Our results showed that the factor inhibiting the in vitro migration of Ehrlich ascites tumor cells was produced from peripheral blood ERFC and CD4 + T cells in patients with gastric and breast cancer, when the cells were stimulated for 2 hr and mostly for 24 hr with 3 M KCl allogeneic extracts corresponding to the kind of carcinoma in patients and containing tumor-associated antigens.
Moreover, this factor could be produced by ERFC from some patients with chronic gastric ulcer after stimulation of the cells with a cancer extracts for 24 hr, but not with extracts of gastric mucosa. Our data from the stimulation of ERFC in cancer and control patients by allogeneic extracts of gastric mucosa and breast tissue showed that the organ-specific antigens did not stimulate the production of the inhibitory factor. In the assay for migration inhibition with Ehrlich cells, the non- At the limiting dilution procedure, cell precursors dispersed in most of the wells of the series of microcultures including those with a low initial cell concentration. Then, the cells proliferated and multiple clones produced an inhibitory factor as the cell number in wells with growing microcultures at the termination of culture exceeded the relatively low number of cells necessary for production of this factor. This explained the lack of significant difference in production of the factor from various initial concentrations of cells in wells. The data for the production of the factor from cancer extract stimulated CD4 + T cells in microcultures were confirmed in patients with breast cancer. As it was shown, in all series of microcultures FrRMs for the supernatants of CD4+ T cells, including FrRMs = 1, was higher than that of ERFC. The production of the factor inhibiting TCM in microcultures of ERFC was determined by the content of CD4 + T cells in ERFC and their activity. Previously, we have indicated that in patients with cancer of the stomach, when active crude supernatants of regional lymph node lymphocytes stimulated with gastric cancer extracts were chromatographed on a Sephadex G-100 column, four active fractions were isolated (5). Inhibition effect against migration of gastric cancer cells was associated with molecular weights ranging between 14,000 and 5,800 for fractions 4 and 5 and lower than 5,800 for fractions 6 and 7. Similar active fractions from crude supernatants were isolated now, although less in number as well as from supernatants of stimulated spleen cells of sarcoma-bearing mice (3) . For the reason of these findings the factor inhibiting TCM could be determined as cytokines probably of protein and mainly of polypeptide nature with molecular heterogeneity. In the present article the term "factor" was used, because cytokines of uncharacterized nature were quite reasonably referred to as "factors" of some defined biological activities (20) .
As the result of our investigations, it has been suggested that the production of the factor with IE against tumor-cell migration, which is one of the elements of the metastatic cascade (21), could be accepted as a protective phenomenon in in vivo tumor pathology probably expressed in blockading the migration of tumor cells in small cancer foci. It could be argued whether this factor is related to Interleukin 10 (IL-10), designated also as cytokine synthesis-inhibitory factor (22) , or supresses the effect of some chemoattractants, particularly autocrine motilitystimulating factors (21,23). Further investigations will be required in this field.
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